31 Mar 2020
COVID-19 outbreak threatens biopharma in-house manufacturing
By Staff Writer
The novel coronavirus is complicating the global biopharma industry’s supply chain because several mega cap biopharma companies have their vital manufacturing steps in Chinese facilities. This is according to leading data and analytics company, GlobalData. Quarantined workforce Supply chain problems in China include a largely quarantined workforce, delays in transporting materials and several other logistical...
